Skip to main content

Table 2 Adverse events in 1st cycle

From: Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015

N = 12

CTC-AE grade (Ver. 4.03)

1

2

3

4

3/4 (%)

Leukopenia

2

2

3

0

3 (25 %)

Neutropenia

1

3

3

0

3 (25 %)

Anemia

1

1

0

0

0 (0 %)

Thrombocytopenia

3

1

0

0

0 (0 %)

Gastritis

0

1

0

0

0 (0 %)

Stroke

0

1

0

0

0 (0 %)

  1. CTC-AE common terminology criteria for adverse events
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us